Market Overview
| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 27.17 Billion |
| Market Size (2030) | USD 38.04 Billion |
| Growth Rate (2025 - 2030) | 6.96% CAGR |
| Fastest Growing Market | Middle East and Africa |
| Largest Market | Asia Pacific |
| Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. |
|
Contraceptive Drugs And Devices Market Analysis by Mordor Intelligence
The contraceptive drugs and devices market is valued at USD 27.17 billion in 2025 and is forecast to reach USD 38.04 billion by 2030, reflecting a 6.96% CAGR. Growth is underpinned by sustained investment in long-acting reversible contraceptives (LARCs), rising demand for non-hormonal methods, and a steady shift toward digital purchasing channels that reduce access barriers. Asia-Pacific accounted for 33.33% of 2024 revenue, buoyed by government family-planning programs, while the Middle East & Africa is on track for the fastest expansion at 8.67% CAGR on the back of new reimbursement schemes that temper cultural resistance.[1]United Nations Population Fund, “UNFPA Supplies Performance Measurement Report 2023,” UNFPA, unfpa.org Devices captured 65.34% of 2024 sales and are tracking an 8.2% yearly gain as implants and hormonal intrauterine devices deliver >99% effectiveness with limited user input. Online distribution, expanding 9.78% per year, is reshaping procurement by pairing telehealth consultations with direct-to-consumer logistics.
Key Report Takeaways
- By product type, devices led with 65.34% revenue share in 2024, while the drugs is advancing at an 7.12% CAGR through 2030.
- By hormonal class, hormonal methods held 61.23% of the contraceptive drugs and devices market share in 2024; non-hormonal options are projected to expand at an 8.78% CAGR to 2030.
- By gender, female-focused products dominated with 80.34% share in 2024, whereas male solutions posted the highest projected CAGR at 8.12% through 2030.
- By age group, 25-34 year-olds accounted for 36.34% of the market in 2024; the 15-24 cohort is on course for a 7.79% CAGR to 2030.
- By distribution channel, retail pharmacies controlled 42.34% of 2024 revenue, but online platforms are climbing at a 9.78% CAGR to 2030.
- By geography, Asia-Pacific held the largest 33.33% share in 2024, while the Middle East and Africa is projected to grow fastest at 8.67% CAGR between 2025-2030.
Global Contraceptive Drugs And Devices Market Trends and Insights
Drivers Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising uptake of LARCs | +2.1% | North America, Europe, Global | Medium term (2-4 years) |
| Expansion of reimbursement & awareness | +1.7% | Asia-Pacific, Middle East & Africa, Global | Medium term (2-4 years) |
| Technological advancement & innovation pipeline | +1.5% | North America, Europe, Global | Long term (≥ 4 years) |
| Shift to e-commerce for OTC barrier products | +0.9% | Developed regions, Global | Short term (≤ 2 years) |
| Rising awareness of family planning | +0.6% | Developing regions, Global | Medium term (2-4 years) |
| Rising global population & unintended pregnancy | +0.8% | Asia-Pacific, Africa, Global | Long term (≥ 4 years) |
Source: Mordor Intelligence
Rising Uptake of Long Acting Reversible Contraceptives
LARCs deliver >99% effectiveness and sharply reduce user error, positioning them as first-line recommendations among clinicians achi.net. Policy shifts such as separate Medicaid reimbursement for immediate postpartum placement lifted utilization by 0.74 percentage points.[2]Journal of Adolescent Health, “Study on Contraceptive Satisfaction Among Youth,” Journal of Adolescent Health, jahonline.org Innovation around biodegradable implants in Phase 1 trials aims to eliminate removal procedures. Cost savings accrue to payers as even modest migration from short-acting pills to LARCs lowers unintended pregnancy rates, strengthening payer support. Together, these dynamics keep the contraceptive drugs and devices market on a structurally higher growth path.
Expansion of Reimbursement Initiatives Coupled with Access and Awareness Programs
A USD 390 million U.S. Title X budget for 2025—up 36%—broadens subsidized access for low-income users. Fourteen other governments maintained or grew allocations, totaling USD 35.3 million.[1]United Nations Population Fund, “UNFPA Supplies Performance Measurement Report 2023,” UNFPA, unfpa.org British Columbia’s province-wide free-contraception policy demonstrates the volume lift when cost barriers vanish, though legacy providers must recalibrate revenue models optionsforsexualhealth.org. Digital partnerships—such as Bayer’s collaborations with Your Life and UNFPA India—blend education and fulfillment, deepening penetration in low- and middle-income countries. These initiatives collectively raise modern‐method prevalence and sustain the contraceptive drugs and devices market expansion.
Technological Advancement and Innovation Pipeline
NIH committed USD 420 million to contraceptive R&D for 2024-2025, earmarking nearly one-third for male solutions. WHO estimates that broadening the method mix could raise global contraceptive prevalence by 8 percentage points by 2030.[3]World Health Organization, “Sexual and Reproductive Health for All,” who.int Next-generation formats range from microneedle patches and six-month injectables to dual-prevention pills that combine pregnancy and HIV protection. Casea S, a biodegradable implant, and Ovaprene, a hormone-free intravaginal ring in Phase 3 trials, illustrate how non-hormonal design addresses the side-effect gap. These pipelines diversify choice and reinforce long-term momentum in the contraceptive drugs and devices market.
Shift to E-commerce for OTC Barrier Products
Barrier products are increasingly purchased online, boosting segment growth at 10.20% CAGR. Telecontraception merges web-based consultations with doorstep delivery, expanding access especially in rural areas. Yet counterfeit risk is material; FDA seizures of fake contraceptives rose 43% in 2024. Platforms are responding with authentication tech and pharmacist-chat features to safeguard users. Overall, digital channels complement brick-and-mortar outlets and widen the contraceptive drugs and devices market footprint.
Restraints Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Cultural-religious barrier in contraceptive adoption | –0.8% | Middle East & Africa, parts of Asia-Pacific & Latin America | Long term (≥ 4 years) |
| Side effects and perceived risk factors | –0.5% | Global | Medium term (2-4 years) |
| Regulatory issues & counterfeit proliferation | –0.3% | Developing regions, Global | Medium term (2-4 years) |
| High upfront device cost & limited rural access | –0.4% | Developing regions, rural areas | Medium term (2-4 years) |
Source: Mordor Intelligence
Cultural-Religious Barrier in Adoption of Contraceptives
Religious objections account for 37% of non-use in Saudi Arabia, 42% in Nigeria, and 28% in Pakistan. Countries with strong faith influence post contraceptive prevalence rates 18 points lower than peers of similar income. Policy examples, such as Indiana’s Medicaid restrictions on IUDs, illustrate the institutionalization of such barriers. Province-level disparities in Mozambique underline localized nuance contraceptionmedicine.biomedcentral.com. Manufacturers increasingly engage religious leaders and deploy community outreach to soften resistance and protect the contraceptive drugs and devices market trajectory.
Regulatory Issues and Proliferation of Counterfeit Products
Thirty-nine percent of seized counterfeit medicines in 2024 were contraceptives, underscoring quality risks in informal channels. Regulatory divergence creates complexity: while 29 U.S. jurisdictions now allow pharmacist prescribing, other regions still mandate physician visits, slowing adoption. Harmonizing standards and boosting post-market surveillance remain industry priorities.
Segment Analysis
By Product Type: Devices Dominate Through Efficacy Advantage
Devices held 65.34% of 2024 revenue, giving them the largest contraceptive drugs and devices market share thanks to the >99% effectiveness of IUDs and implants. The category is growing 6.23% annually as biodegradable implants and extended-duration hormonal IUDs boost uptake. Hormonal IUDs also treat heavy bleeding, adding clinical appeal. Emerging non-hormonal devices like Ovaprene aim to address the side-effect-conscious segment.
Drug-based products represented the remaining 34.66% in 2024 but face faster growth. The contraceptive drugs and devices market size for emergency pills is nevertheless expanding in markets where awareness of the 72-hour window rises. FDA clearance of Opill for OTC sale in March 2024 removes prescription friction and could revive pill volumes.
Note: Segment shares of all individual segments available upon report purchase
By Hormonal Class: Non-Hormonal Methods Gain Momentum
Hormonal methods controlled 61.23% revenue, yet non-hormonal alternatives are expanding 8.78% yearly, far above the total contraceptive drugs and devices market CAGR. Copper IUD demand is also rising as users seek hormone-free choices. Ovaprene’s 86-91% efficacy in early studies suggests a strong commercial outlook.
Lower-dose hormonal innovations seek to mitigate systemic effects while maintaining efficacy. Meanwhile, the Gates Foundation’s USD 280 million annual pledge to non-hormonal R&D underscores investor conviction. This funding influx is expected to expand the contraceptive drugs and devices market size for hormone-free solutions.
By Gender: Male Contraception Emerges as Growth Frontier
Female-focused products captured 80.34% of 2024 sales, underpinned by an extensive product mix spanning pills, rings, implants, and IUDs. The CE-marked FemBloc system introduces the first non-surgical permanent option, reinforcing innovation breadth.
Male methods, currently at 19.66%, are expanding 8.12% annually as societal attitudes shift. Plan A, a reversible hydrogel in Australian trials, and the Galactic Cap are illustrative of the R&D pipeline. A 2025 JAMA survey found 78% of men aged 18-45 willing to adopt novel contraception, signaling meaningful latent demand.
By Age Group: Youth Segment Drives Future Growth
Consumers aged 25-34 commanded 36.34% of 2024 spending, aligning with higher fertility management needs. They are 31% more likely than 15-24 year-olds to adopt modern methods.
The 15-24 cohort, however, is the fastest-growing at 7.79% CAGR to 2030. Dissatisfaction with hormonal side effects, cited by 42% in a U.S. study, propels interest in user-friendly non-hormonal options. Telehealth channels resonate strongly with this digital-native segment, expanding awareness and access.
Note: Segment shares of all individual segments available upon report purchase
By Distribution Channel: Online Platforms Revolutionize Access
Retail pharmacies maintained 42.34% share in 2024, spotlighted by pharmacist-prescribed programs in 29 states and D.C. edition.cnn.com. OTC Opill at USD 19.99 per month further strengthens this channel.
Online portals are scaling at 9.78% CAGR, integrating virtual consultations and discreet home delivery. Telehealth contraceptive prescriptions almost doubled between 2023-2025, with rural usage surging. Authenticity challenges remain; FDA seizures of counterfeit goods rose 43% year-on-year prompting platforms to tighten supply-chain verification.
Geography Analysis
North America benefits from strong reimbursement, with USD 390 million Title X funding in 2025 and OTC Opill availability that removes prescription hurdles. Nonetheless, initiatives such as Project 2025 threaten to curtail free emergency contraception for 48 million women, creating policy uncertainty.
Asia-Pacific holds the largest regional position with 33.33% share, yet intra-regional disparities persist. Only 20.2% of Bangladeshi women wishing to avoid pregnancy use LARCs, highlighting sizeable runway. Digital distribution and expanded reimbursement are expected to narrow this gap.
The Middle East & Africa’s 8.67% CAGR through 2030 stems from enhanced funding and outreach, such as Zambia’s plan to lift prevalence to 40% by 2026 scorecard.prb.org. Youth surveys in Uganda reveal 72.4% intend to use contraception once barriers ease.
Europe’s mature market posts steady growth amid varied method mixes; hormonal usage ranges from 28% in southern to 54% in northern states. EMA approvals of three formulations in 2024 sustain product refresh cycles.
South America registers solid demand where no-cost LARCs drive adherence; Brazil reports 82.1% continuation for LNG IUDs at 24 months, validating public-sector procurement strategies.
Competitive Landscape
Bayer AG leverages the Mirena franchise and pledges contraception access for 100 million women by 2030. Organon & Co. derives 27% of 2022 revenue from Nexplanon and NuvaRing, underscoring its stake in the contraceptive drugs and devices market.
Innovation-centric players gain visibility: Daré Bioscience advances Ovaprene and Casea S, partnering with Theramex to commercialize biodegradable implants ir.darebioscience.com. NEXT Life Sciences raised USD 20 million for Plan A, highlighting investor appetite for male solutions. Competitive intensity is rising as incumbents and start-ups jostle to fill unmet needs with differentiated delivery systems, dosage profiles, and gender-balanced portfolios.
Contraceptive Drugs And Devices Industry Leaders
-
Bayer AG
-
Teva Pharmaceutical Industries Ltd
-
Johnson and Johnson
-
Organon
-
CooperSurgical Inc.
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF
Recent Industry Developments
- March 2025: NEXT Life Sciences began Australian trials of Plan A™, a reversible male contraceptive lasting up to 10 years.
- March 2025: Femasys secured CE mark for FemBloc, the first non-surgical permanent birth-control device.
- February 2025: Daré Bioscience and Theramex agreed to co-develop Casea S, an 18-24-month biodegradable implant.
- January 2025: Daré Bioscience highlighted Ovaprene progress at the J.P. Morgan Women’s Health Series.
Global Contraceptive Drugs And Devices Market Report Scope
As per the scope of the report, contraception is defined as the intentional prevention of conception through the use of various devices, sexual practices, chemicals, drugs, or surgical procedures to prevent a woman from becoming pregnant and avoid the transmission of sexually transmitted diseases. These devices and drugs function by acting as a physical barrier between the sperm and ovum or by changing the mechanism of ovulation. The Contraceptive Drugs and Devices Market is segmented by Products (Drugs (Oral Contraceptives, Topical Contraceptives, and Contraceptive Injectables), Devices (Condoms, Diaphragms, Cervical Caps, Sponges, Vaginal Rings, IUDs, and Other Devices)), Gender (Male and Female), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Product Type | Drugs | Oral Pills | ||
| Transdermal Patch | ||||
| Injectable Contraceptives | ||||
| Emergency Pills | ||||
| Devices | Barrier Devices | Male Condom | ||
| Female Condom | ||||
| Diaphragm | ||||
| Cervical Cap | ||||
| Contraceptive Sponge | ||||
| Long-Acting Reversible | Hormonal IUD | |||
| Copper IUD | ||||
| Sub-dermal Implant | ||||
| Vaginal Ring | ||||
| Permanent | Tubal Occlusion Device | |||
| By Hormonal Class | Hormonal Methods | |||
| Non-Hormonal Methods | ||||
| By Gender | Male | |||
| Female | ||||
| By Age Group | 15-24 Years | |||
| 25-34 Years | ||||
| 35-44 Years | ||||
| 45+ Years | ||||
| By Distribution Channel | Hospital Pharmacies | |||
| Retail Pharmacies & Drug Stores | ||||
| Online Channels | ||||
| Geography | North America | United States | ||
| Canada | ||||
| Mexico | ||||
| Europe | Germany | |||
| United Kingdom | ||||
| France | ||||
| Italy | ||||
| Spain | ||||
| Rest of Europe | ||||
| Asia-Pacific | China | |||
| Japan | ||||
| India | ||||
| Australia | ||||
| South Korea | ||||
| Rest of Asia-Pacific | ||||
| Middle East and Africa | GCC | |||
| South Africa | ||||
| Rest of Middle East and Africa | ||||
| South America | Brazil | |||
| Argentina | ||||
| Rest of South America | ||||
By Product Type
| Drugs | Oral Pills | ||
| Transdermal Patch | |||
| Injectable Contraceptives | |||
| Emergency Pills | |||
| Devices | Barrier Devices | Male Condom | |
| Female Condom | |||
| Diaphragm | |||
| Cervical Cap | |||
| Contraceptive Sponge | |||
| Long-Acting Reversible | Hormonal IUD | ||
| Copper IUD | |||
| Sub-dermal Implant | |||
| Vaginal Ring | |||
| Permanent | Tubal Occlusion Device | ||
By Hormonal Class
| Hormonal Methods |
| Non-Hormonal Methods |
By Gender
| Male |
| Female |
By Age Group
| 15-24 Years |
| 25-34 Years |
| 35-44 Years |
| 45+ Years |
By Distribution Channel
| Hospital Pharmacies |
| Retail Pharmacies & Drug Stores |
| Online Channels |
Geography
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
Need A Different Region or Segment?
Customize Now
Key Questions Answered in the Report
1. What is the current size of the contraceptive drugs and devices market?
The market is valued at USD 27.17 billion in 2025 and is projected to reach USD 38.04 billion by 2030.
2. Which product category leads the market?
Devices dominate with 65.37% revenue share in 2024, driven by the effectiveness and convenience of IUDs and implants.
3. Why are non-hormonal methods growing faster than hormonal options?
Rising consumer concern over hormonal side effects and expanding R&D investment in hormone-free technologies are propelling a 8.78% CAGR for non-hormonal products.
4. How is e-commerce changing contraceptive access?
Online channels, growing at 9.78% per year, integrate telehealth consultations with doorstep delivery, expanding reach to rural and privacy-conscious users.
5. Which region is expanding fastest?
The Middle East & Africa is forecast to grow at 8.67% CAGR between 2025-2030, driven by new reimbursement programs and awareness campaigns.
6. What innovations are emerging in male contraception?
Pipeline products such as Plan A hydrogel and the Galactic Cap aim to offer reversible, hormone-free male options, with early clinical trials underway.
